Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
108 hedge funds and large institutions have $2.09B invested in Rubius Therapeutics, Inc in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 23 reducing their positions, and 21 closing their positions.
1,082% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $1.02M
91% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 23
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
3% more funds holding
Funds holding: 105 → 108 (+3)
6% less capital invested
Capital invested by funds: $2.23B → $2.09B (-$139M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$45M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$9.29M |
| 3 |
Citigroup
New York
|
+$4.49M |
| 4 |
Two Sigma Investments
New York
|
+$3.72M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$14.6M |
| 2 |
AG
Artal Group
Luxembourg
|
-$6.25M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$5.14M |
| 4 |
BlackRock
New York
|
-$5.05M |
| 5 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$4.39M |
RUBY Hedge Fund Activity: Q2 2021 in Review
108 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q2 2021, worth a combined $2.09B — down 6.2% from $2.23B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RUBY positions and 21 closed out — a net gain of 3 holders — while 44 added to existing stakes and 23 trimmed.
The largest buyer was State Street, adding an estimated $45M. The largest seller was Deerfield Management, exiting entirely with an estimated $14.6M sold.
- 108 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q2 2021, up from 105 in Q1 2021.
- Funds reported $2.09B of Rubius Therapeutics, Inc stock for Q2 2021, down 6.2% quarter-over-quarter.
- 24 funds opened new Rubius Therapeutics, Inc positions in Q2 2021 and 21 closed out, a net change of +3 holders.
- The largest Rubius Therapeutics, Inc buyer in Q2 2021 was State Street, an estimated $45M added.
- The largest Rubius Therapeutics, Inc seller in Q2 2021 was Deerfield Management, an estimated $14.6M sold.
Based on aggregated 13F filings for Q2 2021.